arrow
P

Paolo F. Caimi

cleveland clinic
H指数:43
被引数:8,344

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Neighborhood socioeconomic disadvantage and distance from treatment center do not impact survival outcomes of patients with non-Hodgkin lymphoma and multiple myeloma treated with CAR T-cell therapies.

社区社会经济劣势和距离治疗中心的距离不影响接受CAR T细胞疗法治疗的非霍奇金淋巴瘤和多发性骨髓瘤患者的生存结局。

2026-06-100
PRE
Outcomes of tafasitamab and lenalidomide in large B-cell lymphoma based on prior CD19-directed CAR T exposure

基于先前CD19定向CAR T暴露的大B细胞淋巴瘤中Tafasitamab和Lenalidomide的治疗效果

2025-11-180
OAAI
B-Cell Lymphomas 3.2025 Featured Updates to the NCCN Guidelines

B细胞淋巴瘤 3.2025 NCCN指南特色更新

2025-10-010
PRE
Camidanlumab Tesirine in Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 Study

Camidanlumab Tesirine 在复发或难治性经典型霍奇金淋巴瘤中的应用:一项 II 期研究

2025-08-190
OAAI
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Brooks, T.R.; Zabor, E.C.; Bedelu, Y.; Yang, X.; Karimi, Y.H.; Nedved, A.N.; Wang, Y.; Dave, N.K.; Landsburg, D.J.; Baron, K.; et al. 接受epcoritamab或glofitamab治疗的侵袭性B细胞淋巴瘤患者的真实世界结局。Blood 2025, in press. [Google Scholar] [CrossRef]

Blood
IF23.1
2025-07-170
PRE
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trial

使用现场制备的CAR T细胞治疗非霍奇金淋巴瘤:一项双中心、1期临床试验

2025-03-010
OAAI
Addition or Substitution of Acalabrutinib in Intensive Frontline Chemoimmunotherapy for Patients ≤ 70 Years Old with Mantle Cell Lymphoma: Outcomes of the 3-Arm Randomized Phase II Intergroup Trial ECOG-ACRIN EA4181

在≤70岁套细胞淋巴瘤患者强化一线化疗免疫治疗中添加或替代Acalabrutinib:ECOG-ACRIN EA4181三臂随机Ⅱ期协作组试验的结果

BLOOD
IF23.1
2024-11-051
PRE
Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study

真实世界中使用双特异性T细胞衔接器(REALBiTE)治疗复发或难治性大B细胞淋巴瘤的结局:一项多中心、回顾性队列研究

BLOOD
IF23.1
2024-11-051
PRE
MANTLE CELL, FOLLICULAR, WALDENSTROM'S, AND OTHER INDOLENT B CELL LYMPHOMAS: CLINICAL AND EPIDEMIOLOGICAL

套细胞型、滤泡型、Waldenström's以及其他惰性B细胞淋巴瘤:临床与流行病学

BLOOD
IF23.1
2024-11-050
PRE
Evaluation of prognostic factors in patients with high-risk classical Hodgkin lymphoma undergoing autologous transplantation
2024-10-230
OAAI
Targeting CD19-positive lymphomas with the antibody- drug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy
2024-05-093
OAAI
BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation
2024-03-251
OAAI
A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia
2024-03-135
OAAI
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

在LOTIS-2临床试验中接受loncastuximab tesirine治疗的老年和年轻患者的临床结果

2023-12-282
OAAI
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
2023-12-135
OAAI